AI-Driven Pharmacometrics and Clinical Implementation of Model-informed Precision Dosing
The Mizuno Lab advances precision therapeutics by integrating pharmacometrics, AI/ML, and mechanism-based systems pharmacology to develop quantitative tools that directly support clinical decision making. Our mission is to bring model-informed and AI-enabled dosing strategies into real-world patient care, ensuring that each child receives the right drug, at the right dose, at the right time.
Most medications on the market come with dosage recommendations for the average patient. However, drug exposure, therapeutic benefit, and toxicity vary widely among individuals—particularly in neonates, infants, and critically ill patients. By combining data-driven models, AI-enabled predictions, and mechanistic insights into pharmacology, physiology, and disease, we aim to fundamentally improve how clinicians personalize therapy at the bedside.
A major focus of our lab is the clinical implementation of model-informed precision dosing (MIPD). We are actively developing Bayesian and ML-based dosing algorithms, digital twins, and EHR-integrated decision support dashboards that deliver real-time, patient-specific dosing recommendations. These tools are designed to enhance therapeutic outcomes in complex conditions such as inflammatory bowel disease, critical illness, and immune-mediated disorders.
In parallel, we leverage quantitative modeling and simulation to accelerate and optimize drug development. Our work spans clinical trial design, pediatric dose selection, model-informed individualized dosing in clinical trials, and advanced pharmacometric analyses.
As part of Pharmacometrics Services at Cincinnati Children’s, the Mizuno Lab provides clinical pharmacology and model-informed drug development (MIDD) consulting to academic programs and biopharmaceutical partners—bridging innovative quantitative methods with meaningful patient impact.
